2. Search Result
Search Result
Results for "

Jun

" in MedChemExpress (MCE) Product Catalog:

108

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

8

Peptides

8

Natural
Products

11

Recombinant Proteins

4

Isotope-Labeled Compounds

32

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12270
    T-5224
    Maximum Cited Publications
    100 Publications Verification

    		 AP-1 MMP Neurological Disease Inflammation/Immunology Cancer
    T-5224 is a transcription factor c-Fos/activator protein (AP)-1 inhibitor with anti-inflammatory effects, which specifically inhibits the DNA binding activity of c-Fos/c-Jun without affecting other transcription factors. T-5224 inhibits the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription .
    T-5224
  • HY-13241
    Ralimetinib dimesylate
    10+ Cited Publications

    LY2228820 dimesylate

    		 p38 MAPK Autophagy Apoptosis Inflammation/Immunology Cancer
    Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.
    Ralimetinib dimesylate
  • HY-N2593
    Isorhapontigenin
    4 Publications Verification

    		 Carnitine Palmitoyltransferase (CPT) Reactive Oxygen Species (ROS) Autophagy Apoptosis NF-κB PI3K Akt MMP Keap1-Nrf2 Metabolic Disease Inflammation/Immunology Cancer
    Isorhapontigenin is an orally active dietary polyphenol. Isorhapontigenin acts as a potent antioxidant that reduces the production of reactive oxygen species (ROS). Isorhapontigenin promotes the binding of JUN to the AP-1 site on the SESN2 promoter, induces SESN2 transcription, triggers MAPK8-dependent JUN activation, and upregulates the expression of PPAR-α, PGC-1α and CPT-1A to facilitate fatty acid oxidation. Isorhapontigenin induces autophagy, apoptosis and preadipocyte differentiation; it inhibits tumor growth, cell invasion, NF-κB transcriptional activity, the PI3K/Akt signaling pathway, STAT1 phosphorylation and MMP-2 expression. Isorhapontigenin alleviates oxidative stress, inflammatory cytokine release and triglyceride accumulation; it increases intracellular ATP levels and promotes Nrf2 nuclear translocation. Isorhapontigenin improves insulin sensitivity in adipose tissue and glucose tolerance, and reduces postprandial blood glucose, insulin and free fatty acid levels. Isorhapontigenin is applicable to research on bladder cancer, liver injury, chronic obstructive pulmonary disease, acute lung injury and type 2 diabetes .
    Isorhapontigenin
  • HY-B1198
    Piperonyl butoxide
    1 Publications Verification

    ENT-14250

    		 Environmental Pollutants Parasite Infection Cancer
    Piperonyl butoxide (ENT-14250) is a pesticide synergist and food additive. Piperonyl butoxide has adverse effects on reproduction, development and behavior in mice. Piperonyl butoxide can activate c-Jun and ATF-2 in mouse hepatocytes. Piperonyl butoxide is a liver cancer carcinogen in rats and mice .
    Piperonyl butoxide
  • HY-128326
    ZAK-IN-1

    		MAP3K Cardiovascular Disease
    ZAK-IN-1 is an orally active and selective selective leucine-zipper and sterile‑α motif kinase (ZAK) inhibitor with IC50 of 4 nM and KD of 8 nM. ZAK-IN-1 exhibits excellent selectivity against a panel of 403 wild-type kinases. ZAK-IN-1 blocks p38/GATA-4 and JNK/c-Jun signaling and shows promising anti antihypertrophic cardiomyopathy (HCM) efficacy. ZAK-IN-1 can be used for the study of HCM .
    ZAK-IN-1
  • HY-13866
    Ro 31-8220 mesylate
    10+ Cited Publications

    Ro 31-8220 methanesulfonate; Bisindolylmaleimide IX mesylate

    		 PKC JNK Cardiovascular Disease Neurological Disease Cancer
    Ro 31-8220 mesylate is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7. Ro 31-8220 mesylate can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC .
    Ro 31-8220 mesylate
  • HY-114332
    GNE-8505

    		MAP3K JNK Neurological Disease Metabolic Disease
    GNE-8505 is an orally active, blood-brain barrier-permeable selective dual leucine zipper kinase (DLK) inhibitor. GNE-8505 inhibits the DLK/JNK pathway, reduces stress-induced c-Jun phosphorylation levels, decreases neuronal death and suppresses axonal degeneration. GNE-8505 reduces phosphorylated c-Jun levels in the retina, spinal cord and brain tissues of mice. GNE-8505 is applicable to research related to Alzheimer's disease and amyotrophic lateral sclerosis (ALS) .
    GNE-8505
  • HY-107598
    JNK Inhibitor VIII
    3 Publications Verification

    TCS JNK 6o

    		 JNK Cancer
    JNK Inhibitor VIII (TCS JNK 6o) is a c-Jun N-terminal kinases (JNK-1, -2, and -3) inhibitor with Ki values of 2 nM, 4 nM, 52 nM, respectively, and has IC50 values of 45 nM and 160 nM for JNK-1 and -2, respectively .
    JNK Inhibitor VIII
  • HY-138304
    CC-90001
    3 Publications Verification

    		 JNK Inflammation/Immunology
    CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis .
    CC-90001
  • HY-148510
    HKB99

    		Phosphatase Apoptosis Akt ERK Reactive Oxygen Species (ROS) Cancer
    HKB99 is an allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1). HKB99 induces apoptosis. HKB99 inhibits the formation of invasive pseudopodia and inhibits migration. HKB99 increases the oxidative stress, activates JNK/c-Jun and suppresses AKT and ERK. HKB99 can be used for the research of non-small-cell lung cancer (NSCLC) .
    HKB99
  • HY-141582
    Ceramide 3

    N-Stearoyl phytosphingosine

    		 JNK NF-κB Interleukin Related TNF Receptor Inflammation/Immunology
    Ceramide 3 (N-Stearoyl phytosphingosine) is an orally active major component of intercellular lipids in the stratum corneum of the skin, and belongs to the ceramide family. Ceramide 3 inhibits c-jun and NF-κB activation induced by Histamine (HY-B1204), and suppresses the expression of IL-4 and TNF-α. Ceramide 3 inhibits scratching behavior and vascular permeability in mice, and exhibits antihistamine effects in guinea pig ileum. Ceramide 3 improves skin barrier function, reduces transepidermal water loss, erythema and the number of circulating epidermal cells, and accelerates barrier repair of irritated or dysfunctional skin .
    Ceramide 3
  • HY-11010
    AS601245
    5+ Cited Publications

    		 JNK Neurological Disease Inflammation/Immunology Cancer
    AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties .
    AS601245
  • HY-N5048
    Galloylpaeoniflorin

    6'-O-Galloyl paeoniflorin

    		 NF-κB ERK JNK Nuclear Factor of activated T Cells (NFAT) Keap1-Nrf2 PI3K Akt Reactive Oxygen Species (ROS) Apoptosis DNA/RNA Synthesis Infection Neurological Disease Metabolic Disease Inflammation/Immunology
    Galloylpaeoniflorin (6'-O-Galloyl paeoniflorin) is an orally active galloylated derivative of Paeoniflorin (HY-N0293) found in peony roots with various anti-inflammatory and antioxidant activities. Galloylpaeoniflorin suppresses RANKL-induced activation of ERK, JNK, c-Fos, c-Jun, and NFATc1, and reduces osteoclast-specific gene expression. Galloylpaeoniflorin activates Nrf2 and PI3K/Akt pathways, inhibits NF-κB activation, and scavenges ROS to reduce oxidative DNA, lipid, and protein damage. Galloylpaeoniflorin attenuates neuroinflammation, inhibits apoptosis, reduces Helicobacter pylori-induced gastric mucosa injury and UVB-induced cell damage. Galloylpaeoniflorin can be used for the research of osteoporosis, gastritis, ischemic stroke and skin diseases .
    Galloylpaeoniflorin
  • HY-N6983
    Licoricesaponin G2

    		TNF Receptor PI3K Akt mTOR Reactive Oxygen Species (ROS) Inflammation/Immunology Cancer
    Licoricesaponin G2 is an orally active component found in Licorice. Licoricesaponin G2 significantly ameliorates Bleomycin (HY-108345)-induced pulmonary fibrosis by inhibiting the TNF-α signaling pathway, reducing epithelial-mesenchymal transition, and decreasing extracellular matrix deposition. Licoricesaponin G2 inhibits cancer cells proliferation, migration, inhibits PI3K/AKT/mTOR signaling pathway and increases ROS production. Licoricesaponin G2 can be used for the research of lung cancer and pulmonary fibrosis .
    Licoricesaponin G2
  • HY-W050000
    OR-1855
    1 Publications Verification

    		 Drug Metabolite Reactive Oxygen Species (ROS) ERK p38 MAPK Cardiovascular Disease Inflammation/Immunology
    OR-1855, an active metabolite of Levosimendan (HY-14286), has effect on myometrial contractility. OR-1855 exerts anti-inflammatory effects by inhibiting IL-1β-induced ROS formation and NAD(P)H oxidase-dependent superoxide radical generation in HUVECs. OR-1855 inhibits IL-1β-induced phosphorylation p38 MAPK, ERK1/2, c-Jun and JNK in HUVECs. OR-1855 can be used for the study of inflammation .
    OR-1855
  • HY-162723
    FOSL1 degrader 1

    		PROTACs AP-1 Cancer
    FOSL1 degrader 1 is a FOSL1 PROTAC degrader with a DC50 of 2.3 μM. FOSL1 degrader 1 induces proteasomal degradation of FOSL1. FOSL1 degrader 1 eliminates cancer stem cells in head and neck squamous cell carcinoma. FOSL1 degrader 1 suppresses head and neck squamous cell carcinoma tumorigenesis. FOSL1 degrader 1 can be used for the research of head and neck squamous cell carcinoma .
    FOSL1 degrader 1
  • HY-145601
    Tinengotinib

    TT 00420

    		 Aurora Kinase FGFR VEGFR Cancer
    Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting Aurora A/B (IC50=1.2-3.3 nM), FGFR1/2/3 (IC50=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R. Tinengotinib blocks Aurora kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment .
    Tinengotinib
  • HY-B1451
    Imidapril hydrochloride

    TA-6366

    		 Angiotensin-converting Enzyme (ACE) MMP JNK Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Imidapril hydrochloride (TA-6366) is an orally active dual inhibitor of angiotensin-converting enzyme (ACE) and MMP-9. Imidapril hydrochloride inhibits lipopolysaccharide-induced phosphorylation of c-Jun, MKK4 and JNK in monocytes, and downregulates the production of specific inflammatory factors such as TNF-α and IP-10, thereby exerting anti-inflammatory activity. Imidapril hydrochloride also effectively ameliorates mesangial expansion and reduces urinary albumin excretion by inhibiting angiotensin AngII production, lowering glomerular pressure and oxidative stress, thus delaying disease progression. Imidapril hydrochloride can also directly bind to the active site of MMP-9 to inhibit gelatinase activity, and suppress the enlargement of cerebral aneurysms without altering systemic blood pressure. Imidapril hydrochloride is widely applicable to related studies on autoimmune glomerulonephritis, diabetic nephropathy, cerebral aneurysms and other conditions .
    Imidapril hydrochloride
  • HY-107599
    AEG3482

    		JNK Apoptosis Neurological Disease
    AEG3482 is a potent antiapoptotic compound that inhibits Jun kinase (JNK) activity through induced expression of heat shock protein 70 (HSP70). AEG3482 directly binds HSP90, thereby facilitating HSF1-dependent expression of HSP70 and HSP25 .
    AEG3482
  • HY-114331
    DLK-IN-1

    		MAP3K FLT3 PAK STK33 Trk Receptor Neurological Disease
    DLK-IN-1 (Compound 14) is an orally active, blood-brain barrier-penetrable and selective inhibitor of dual leucine zipper kinase (DLK, MAP3K12) with a Ki value of 3 nM. DLK-IN-1 inhibits Flt3, PAK4, STK33 and TrkA. DLK-IN-1 reduces p-c-Jun. DLK-IN-1 can be used in Alzheimer's disease research .
    DLK-IN-1
  • HY-W010983
    SC-236
    2 Publications Verification

    		 COX PPAR Apoptosis Cardiovascular Disease Inflammation/Immunology Cancer
    SC-236 is an orally active COX-2 specific inhibitor (IC50 = 10 nM) and a PPARγ agonist. SC-236 suppresses activator protein-1 (AP-1) through c-Jun NH2-terminal kinase. SC-236 exerts anti-inflammatory effects by suppressing phosphorylation of ERK in a murine model .
    SC-236
  • HY-152142
    DN-1289
    1 Publications Verification

    		 JNK Neurological Disease
    DN-1289 is an orally active and selective inhibitor of dual leucine zipper kinase (DLK; IC50=17 nM) and leucine zipper-bearing kinase (LZK; IC50=40 nM). DN-1289 results significant attenuation of optic nerve crush (ONC)-induced p-c-Jun in mice model. DN-1289 has excellent in vivo plasma half-life and blood-brain barrier permeability .
    DN-1289
  • HY-160469
    INY-05-040

    		Akt PROTACs Cancer
    INY-05-040 is an AKT degrader that can selectively and quickly degrade all three AKT isoforms. INY-05-040 exhibits anti-cancer activity. INY-05-040 can inhibit downstream signaling and cell proliferation in 288 cancer cell lines. INY-05-040 can suppress AKT signaling and induces the stress mitogen-activated protein kinase (MAPK) c-Jun N-terminal kinase (JNK). INY-05-040 is effective for breast cancer lines with a low-baseline activation of stress MAPK pathway. INY-05-040 can be studied for anti-cancer research .
    INY-05-040
  • HY-172920
    Wnt/β-catenin-IN-6

    		Wnt β-catenin EGFR ERK COX Akt GSK-3 c-Myc Apoptosis Interleukin Related JNK Inflammation/Immunology Cancer
    Wnt/β-catenin-IN-6 is an orally active Wnt/β-catenin pathway inhibitor. Wnt/β-catenin-IN-6 blocks the AKT/GSK-3β/β-catenin signaling pathway, leading to reduced expression of Wnt target genes (c-Myc, c-Jun). Wnt/β-catenin-IN-6 reduces COX2 expression and IL-8 levels, highlighting its dual anti-inflammatory and antitumor effects. Wnt/β-catenin-IN-6 can induce apoptosis. Wnt/β-catenin-IN-6 serves as a tool for non-small cell lung cancer (NSCLC) research .
    Wnt/β-catenin-IN-6
  • HY-157403
    Jun12682
    1 Publications Verification

    		 Virus Protease SARS-CoV Infection
    Jun12682 is an orally active SARS-CoV-2 papain-like protease (PL pro) inhibitor, with a Ki value of 37.7 nM and an EC50 value of 1.1 μM in the FlipGFP PL pro assay. Jun12682 has efficacy in hindering PL pro both deubiquitination and deISGylation, with Ki values of 63.5 and 38.5 nM, respectively. Jun12682 exhibits resistance in multiple PL pro mutant strains, and its enzymatic activity is comparable to that of the wild-type. Jun12682 can be used for the study of the SARS-CoV-2 .
    Jun12682
  • HY-10851
    JNK-9L

    		JNK Reactive Oxygen Species (ROS) Neurological Disease
    JNK-9L (Compound 9l) is a BBB-penetrable and ATP-competitive JNK inhibitor with IC50s of 0.099 and 0.148  μM for JNK1 and JNK3, respectively. JNK-9L significantly inhibits c-jun phosphorylation and Streptozotocin (HY-13753)-induced ROS generation with an IC50 of 0.8  nM. JNK-9L can be used for neurodegenerative disorders like Parkinson’s disease research .
    JNK-9L
  • HY-13866B
    Ro 31-8220 formic
    10+ Cited Publications

    Bisindolylmaleimide IX formic

    		 PKC JNK Cancer
    Ro 31-8220 formic is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 formic also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively). Ro 31-8220 formic can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC .
    Ro 31-8220 formic
  • HY-107621
    U0124

    		MEK Cancer
    U0124, an inactive U0126 analog, has no effect on c-Fos and c-Jun protein or mRNA levels. U0126 is a MEK inhibitor. U0124 does not inhibit MEK at concentrations up to 100 μM .
    U0124
  • HY-107600
    IQ-3
    2 Publications Verification

    		 JNK Inflammation/Immunology
    IQ-3 is a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. IQ-3 exhibits Kd values of 0.24 μM, 0.29 μM and 0.066 μM for JNK1, JNK2 and JNK3, respectively .
    IQ-3
  • HY-114250
    Cantrixil

    TRX-E-002-1

    		 Apoptosis Cancer
    Cantrixil (TRX-E-002-1), an active enantiomer of TRX-E-002, is a second-generation super-benzopyran (SBP) compound. Cantrixil increases phosphorylated c-Jun levels resulting in caspase-mediated apoptosis in ovarian cancer cells. Cantrixil has potent pan anti-cancer activity against a broad range of cancer phenotypes .
    Cantrixil
  • HY-125838
    J30-8

    		JNK Neurological Disease
    J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) with an IC50 of 40 nM, which 2500-fold isoform selectivity against JNK1α1 and JNK2α2. J30-8 exhibits neuroprotective activity in vitro and potential for the treatment of neurodegenerative diseases .
    J30-8
  • HY-W020952
    Palladium(Ⅱ) acetylacetonate

    Palladium(Ⅱ) 2,4-pentanedionate; Pd(acac)2

    		 Biochemical Assay Reagents HSP Eukaryotic Initiation Factor (eIF) IRE1 JNK Apoptosis Cancer
    Palladium(II) acetylacetonate is a metal-organic complex. Palladium(II) acetylacetonate upregulates the expression of GRP78, ATF-4, XBP-1, CHOP, and phosphorylated c-Jun. Palladium(II) acetylacetonate induces Apoptosis. Palladium(II) acetylacetonate has anticancer effects against non-small cell lung cancer, gastric cancer, leukemia, and cervical cancer .
    Palladium(Ⅱ) acetylacetonate
  • HY-13866A
    Ro 31-8220

    Bisindolylmaleimide IX

    		 PKC JNK Cardiovascular Disease Neurological Disease
    Ro 31-8220 is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively), with no effect on MKK3, MKK4, MKK6 and MKK7. Ro 31-8220 can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC .
    Ro 31-8220
  • HY-P1190
    c-JUN peptide

    		JNK Apoptosis Inflammation/Immunology
    c-JUN peptide is a cell-permeable c-JUN-JNK interaction inhibitor. c-JUN peptide inhibits serum-induced c-Jun phosphorylation. c-JUN peptide induces apoptosis .
    c-JUN peptide
  • HY-P10506
    CMX-8933

    		JNK Neurological Disease
    CMX-8933 is an octapeptide fragment of the goldfish brain neurotrophic factor ependymin. CMX-8933 increases the enzymatic activity of c-Jun N-terminal kinase (JNK), increases the phosphorylation of JNK and c-Jun proteins, and increases the cellular levels of c-Jun and c-Fos mRNA. CMX-8933 can be used to study the role of ependymin in neuroplasticity, learning, memory formation, and neural regeneration .
    CMX-8933
  • HY-169021
    JNK-1-IN-3

    		JNK Cancer
    JNK-1-IN-3 (Compound 9e) is an inhibitor of JNK1 that downregulates JNK1 gene expression and inhibits the protein levels of its phosphorylated form, concurrently reducing the expression of its downstream targets, c-Jun and c-Fos, in tumors while restoring p53 activity. JNK-1-IN-3 exhibits broad-spectrum antiproliferative activity, particularly with high inhibitory activity against renal and breast cancer cell lines, demonstrating both in vivo and in vitro anticancer activity .
    JNK-1-IN-3
  • HY-121683
    (E)-2-Hexadecenal

    16:1 Aldehyde; trans-2-Hexadecenal

    		 Mixed Lineage Kinase Apoptosis JNK Microtubule/Tubulin Cancer
    (E)-2-Hexadecenal (trans-2-Hexadecenal) is an MLK3 activator that induces cytoskeletal remodeling, leading to cell rounding, detachment, and ultimately apoptosis in human and mouse cells. (E)-2-Hexadecenal activates the MLK3 signaling pathway, phosphorylating MKK4/7 and JNK, subsequently activating downstream targets of JNK, such as c-Jun phosphorylation, cytochrome c release, Bax activation, Bid cleavage, and Bim translocation to mitochondria. (E)-2-Hexadecenal has potential applications in research related to sphingolipid signaling pathways .
    (E)-2-Hexadecenal
  • HY-N1326
    Santamarine

    Santamarin; Balchanin

    		 JNK p38 MAPK MMP NF-κB COX TNF Receptor Interleukin Related Reactive Oxygen Species (ROS) Apoptosis Mitochondrial Metabolism DNA/RNA Synthesis Keap1-Nrf2 Bcl-2 Family Caspase PARP TGF-beta/Smad Metabolic Disease Inflammation/Immunology Cancer
    Santamarine (Santamarin; Balchanin) is a sesquiterpene lactone found in Artemisia scoparia. Santamarine shows anti-inflammatory, antioxidant, anticancer and anti-photoaging activities. Santamarine suppresses UVA-induced phosphorylation of JNK and p38 MAPK, nuclear translocation of phosphorylated c-Fos and c-Jun, and AP-1-mediated MMP-1 transcription and secretion. Santamarine suppresses NF-κB signaling, iNOS, COX-2, TNF-α, and IL-1β production. Santamarine inhibits thioredoxin reductase activity, induces ROS production, mitochondrial apoptosis, G2/M cell cycle arrest, and DNA damage, and reduces cancer cell growth. Santamarine can be used for the photoaging, inflammatory diseases and cancer .
    Santamarine
  • HY-118529
    JUN-1111

    		Phosphatase Cancer
    JUN-1111 is an irreversible and selective Cdc25 phosphatase inhibitor with IC50 values of 0.38, 1.8, 0.66, 28, 37 µM for Cdc25A, Cdc25B, Cdc25C, VHR, PTP1B, respectively. JUN-1111 induces cell cycle arrest at G1 and G2/M phases. JUN-1111 decreases the expression of phosphoCdk1 .
    JUN-1111
  • HY-P4699
    (Thr17)-c-Jun (11-23)

    		JNK Others
    (Thr17)-c-Jun (11-23) is a fragment peptide of c-Jun.
    (Thr17)-c-Jun (11-23)
  • HY-RS07055
    Jun Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Jun Mouse Pre-designed siRNA Set A contains three designed siRNAs for Jun gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Jun Mouse Pre-designed siRNA Set A
    Jun Mouse Pre-designed siRNA Set A
  • HY-RS07054
    JUN Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    JUN Human Pre-designed siRNA Set A contains three designed siRNAs for JUN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    JUN Human Pre-designed siRNA Set A
    JUN Human Pre-designed siRNA Set A
  • HY-134975
    NY2267

    		c-Myc Cancer
    NY2267 is a disruptor of Myc-Max interaction, with an IC50 of 36.5 μM. NY2267 inhibits Myc- and Jun-induced transcriptional activation .
    NY2267
  • HY-N1961
    Ophiopogonin B

    OP-B

    		 JNK Apoptosis Cancer
    Ophiopogonin B (OP-B) induces the autophagy and apoptosis of colon cancer cells by activating JNK/c-Jun signaling pathway. Ophiopogonin B is a saponin compound isolated from Radix Ophiopogonjaponicus .
    Ophiopogonin B
  • HY-101287
    MPT0B392

    		Microtubule/Tubulin JNK Apoptosis Caspase Cancer
    MPT0B392, an orally active quinoline derivative, induces c-Jun N-terminal kinase (JNK) activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line .
    MPT0B392
  • HY-141582S
    Ceramide 3-d3

    N-Stearoyl phytosphingosine-d3

    		 Isotope-Labeled Compounds Interleukin Related TNF Receptor NF-κB JNK Inflammation/Immunology
    Ceramide 3-d3 (N-Stearoyl phytosphingosine-d3) is deuterium labeled Ceramide 3. Ceramide 3 is an orally active major component of intercellular lipids in the stratum corneum of the skin, and belongs to the ceramide family. Ceramide 3 inhibits c-jun and NF-κB activation induced by Histamine (HY-B1204), and suppresses the expression of IL-4 and TNF-α. Ceramide 3 inhibits scratching behavior and vascular permeability in mice, and exhibits antihistamine effects in guinea pig ileum. Ceramide 3 improves skin barrier function, reduces transepidermal water loss, erythema and the number of circulating epidermal cells, and accelerates barrier repair of irritated or dysfunctional skin.
    Ceramide 3-d3
  • HY-175165
    Jun6504

    		Enterovirus Infection
    Jun6504 is an enterovirus 2C inhibitor. Jun6504 shows potent and broad-spectrum antiviral activity against multiple strains of EV-D68 (EC50 = 250 nM), EV-A71 (EC50 = 502.4 nM), and CVB3 (EC50 = 1049 nM). Jun6504 improves paralysis score and weight gain in a neonatal mouse model of EV-D68 infection. Jun6504 reduces viral titers in the spinal cord and the infected quadriceps muscle. Jun6504 can be used for EV-D68 antiviral research .
    Jun6504
  • HY-168916
    Jun13296

    		SARS-CoV Virus Protease
    Jun13296 is an orally active quinoline SARS-CoV-2 papain-like protease inhibitor (IC50 = 0.13  µM, Ki  = 8.8  nM). Jun13296 exhibits potent inhibition against SARS-CoV-2 variants and Nirmatrelvir (HY-138687)-resistant mutants. Jun13296 improves lung viral titers, and prevents lung tissue damage in a SARS-CoV-2 infection model .
    Jun13296
  • HY-D2898
    Jun14157

    		Fluorescent Dye Enterovirus Infection
    Jun14157 is a fluorescence polarization probe that can specifically bind to the conserved allosteric site of enterovirus 2C proteins (Ex: 485/20; Em: 528/20). Jun14157 has Kd values of 2.3 μM, 1.4 μM, and 1.1 μM for EV-D68 2C, EV-A71 2C, and CVB3 2C, respectively. Jun14157 can be used in research related to enteroviruses .
    Jun14157
  • HY-174814
    Jun15716

    		Enterovirus Infection
    Jun15716 is an Enterovirus (EVs) 2C protein (EVs 2C) inhibitor with Kis of 15.9, 44.2 and 17.8 μM for EV-D68, EV-A71 and CVB3, respectively. Jun15716 has a potent antiviral activity against EV-D68 US/MO/14-18947 and CVB3 Nancy cells (EC50s of 1.0 and 0.7 μM, respectively). Jun15716 can be used for viral infections research, such as meningitis, hand, foot and mouth disease (HFMD) and viral myocarditis .
    Jun15716

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: